Inactive Instrument

Rekah Pharmaceutical Industry Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

IL0010810096

Pharmaceuticals

Financials

Sales 2022 292M 77.79M 29.24B Sales 2023 322M 85.57M 32.17B Capitalization 169M 44.88M 16.87B
Net income 2022 -2M -532K -200M Net income 2023 -6M -1.6M -600M EV / Sales 2022 1.1 x
Net Debt 2022 145M 38.68M 14.54B Net Debt 2023 166M 44.28M 16.64B EV / Sales 2023 1.04 x
P/E ratio 2022
-85.5 x
P/E ratio 2023
-24.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 17.36%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 80 93-08-23
Director of Finance/CFO 44 18-10-31
Director/Board Member 78 93-08-23
Members of the board TitleAgeSince
Director/Board Member 62 15-04-14
Director/Board Member 52 15-04-14
Chairman 77 15-04-14
More insiders
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
More about the company